Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Pharmacokinetics and Pharmacodynamics After Multiple Oral Doses of BIBR 1048 MS Capsule in Healthy Japanese Male Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02171000
Recruitment Status : Completed
First Posted : June 23, 2014
Last Update Posted : June 23, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
To investigate safety, pharmacokinetics and pharmacodynamics of BIBR 1048 MS following oral administration of multiple doses (150 mg b.i.d., 7 days)

Condition or disease Intervention/treatment Phase
Healthy Drug: BIBR 1048 MS Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety, Pharmacokinetics and Pharmacodynamics After Multiple Oral Doses of BIBR 1048 MS Capsule (150 mg b.i.d., 7 Days) in Healthy Japanese Male Subjects (Open Label Study)
Study Start Date : April 2005
Actual Primary Completion Date : May 2005

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: BIBR 1048
BIBR 1048 MS
Drug: BIBR 1048 MS
150 mg capsules, b.i.d, 7 days
Other Name: dabigatran etexilate




Primary Outcome Measures :
  1. Change from baseline in physical examination [ Time Frame: within 14 days prior to drug administration until up to 18 days post drug administration ]
  2. Change from baseline in vital signs [ Time Frame: within 14 days prior to drug administration until up to 18 days post drug administration ]
  3. Change from baseline in 12-lead electrocardiogram (ECG) [ Time Frame: within 14 days prior to drug administration until up to 18 days post drug administration ]
  4. Change from baseline in clinical laboratory tests [ Time Frame: within 14 days prior to drug administration until up to 18 days post drug administration ]
  5. Number of participants with adverse events [ Time Frame: within 14 days prior to drug administration until up to 18 days post drug administration ]

Secondary Outcome Measures :
  1. Changes in activated partial thromboplastin time (aPTT) [ Time Frame: Day 1 and 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h after drug administration (morning), Day 2 to 6 prior drug administration (morning), Day 5 and 6 prior drug administration (evening), Day 7 24, 36, 48 h after final drug administration ]
  2. Changes in ecarin clotting time (ECT) [ Time Frame: Day 1 and 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h after drug administration (morning), Day 2 to 6 prior drug administration (morning), Day 5 and 6 prior drug administration (evening), Day 7 24, 36, 48 h after final drug administration ]
  3. Changes in thrombin time (TT) [ Time Frame: Day 1 and 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h after drug administration (morning), Day 2 to 6 prior drug administration (morning), Day 5 and 6 prior drug administration (evening), Day 7 24, 36, 48 h after final drug administration ]
  4. Changes in prothrombin time expressed as international normalised ratio (INR) [ Time Frame: Day 1 and 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h after drug administration (morning), Day 2 to 6 prior drug administration (morning), Day 5 and 6 prior drug administration (evening), Day 7 24, 36, 48 h after final drug administration ]
  5. Maximum measured concentration of the analyte in plasma (Cmax) [ Time Frame: Day 1 and 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h after drug administration (morning), Day 2 to 6 prior drug administration (morning), Day 5 and 6 prior drug administration (evening), Day 7 24, 36, 48 h after final drug administration ]
  6. Time from dosing to maximum measured concentration of the analyte in plasma (tmax) [ Time Frame: Day 1 and 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h after drug administration (morning), Day 2 to 6 prior drug administration (morning), Day 5 and 6 prior drug administration (evening), Day 7 24, 36, 48 h after final drug administration ]
  7. Area under the concentration-time curve of the analyte in plasma over a uniform dosing interval τ after administration of the single dose on Day 1 (AUCτ,1) [ Time Frame: Day 1 before, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours after drug administration in the morning ]
  8. Amount of analyte that is eliminated in urine from the time point t1 to time point t2 ( Aet1-t2 ) [ Time Frame: Day 1: 0-4, 4-8, 8-12 and 12-24 hours after the first drug administration, on Day 7: 0-4, 4-8, 8-12, 12-24, 24-48 and 48-72 hours after the last drug administration ]
  9. Renal clearance of the analyte from the time point t1 until the time point t2 (CLR,t1-t2 ) [ Time Frame: Day 1: 0-4, 4-8, 8-12 and 12-24 hours after the first drug administration, on Day 7: 0-4, 4-8, 8-12, 12-24, 24-48 and 48-72 hours after the last drug administration ]
  10. Fraction of analyte eliminated in urine from time point t1 to time point t2 (fet1-t2) [ Time Frame: Day 1: 0-4, 4-8, 8-12 and 12-24 hours after the first drug administration, on Day 7: 0-4, 4-8, 8-12, 12-24, 24-48 and 48-72 hours after the last drug administration ]
  11. Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmax,ss) [ Time Frame: Day 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours after final drug administration ]
  12. Time from last dosing to maximum concentration of the analyte in plasma at steady state (tmax,ss) [ Time Frame: Day 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours after final drug administration ]
  13. Minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmin,ss) [ Time Frame: Day 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours after final drug administration ]
  14. Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ (AUCτ,ss) [ Time Frame: Day 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours after final drug administration ]
  15. Terminal rate constant in plasma at steady state (λz,ss) [ Time Frame: Day 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours after final drug administration ]
  16. Terminal half-life of the analyte in plasma at steady state (t1/2,ss) [ Time Frame: Day 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours after final drug administration ]
  17. Mean residence time of the analyte in the body at steady state after po administration (MRTpo,ss) [ Time Frame: Day 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours after final drug administration ]
  18. Apparent clearance of the analyte in the plasma at steady state after extravascular multiple dose administration (CL/F,ss) [ Time Frame: Day 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours after final drug administration ]
  19. Apparent volume of distribution during the terminal phase λz at steady state following extravascular administration (Vz/F,ss) [ Time Frame: Day 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours after final drug administration ]
  20. Amount of analyte that is eliminated in urine at steady state from the time point t1 to time point t2 (Aet1-t2,ss) [ Time Frame: Day 7 : 0-4, 4-8, 8-12, 12-24, 24-48 and 48-72 hours after the last drug administration ]
  21. Fraction of analyte eliminated in urine at steady state from time point t1 to time point t2 (fet1-t2,ss) [ Time Frame: Day 7: 0-4, 4-8, 8-12, 12-24, 24-48 and 48-72 hours after the last drug administration ]
  22. Renal clearance of the analyte in plasma from the time point t1 until the time point t2 at steady state (CLR,t1-t2,ss) [ Time Frame: Day 7 prior, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours after final drug administration ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy male subjects according to the following criteria:

    Based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate and body temperature), 12-lead ECG, clinical laboratory tests

    • 1.1 No finding of clinical relevance
    • 1.2 No evidence of a clinically relevant concomitant disease
  2. Age ≥20 and Age ≤35 years
  3. Body Mass Index (BMI) ≥18 and BMI <25 kg/m2 (Body Mass Index)
  4. Signed and dated written informed consent prior to admission to the trial in accordance with Japanese GCP (Ministry of Health, Labour and Welfare Ordinance No.28, March 27, 1997).

Exclusion Criteria:

  1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  2. Subject was not able to use an adequate form of contraception from the time of the first dose on Day 1 up to end-of study examination
  3. Diseases of the central nervous system (such as epilepsy), psychiatric disorders or neurological disorders
  4. History of clinically significant orthostatic hypotension, clinically significant current or past fainting spells or blackouts.
  5. Chronic or relevant acute infections
  6. History of

    • allergy/hypersensitivity (including drug allergy) which was deemed relevant to the safety assessment as judged by the investigator (excluding asymptomatic seasonal rhinitis/hay fever)
    • any bleeding disorder including prolonged or habitual bleeding
    • other hematologic diseases
    • cerebral bleeding (e.g. after a car accident)
    • concussions (head trauma resulting in injuring to brain) with or without loss of consciousness
  7. Intake of drugs with a long half-life (> 24 hours) within at least 1 month or less than 10 half-lives, whichever was shorter, of the respective drug prior to administration or during the trial
  8. Use of aspirin (including over-the-counter medications), antiplatelet agents like ticlopidine or dipyridamole, chronic administration of non-steroidal anti-inflammatory drugs (NSAIDs, coumadin like anticoagulants, chronic use of corticosteroids, heparin or fibrinolytic agents within 14 days prior to administration up to end-of-study examination
  9. Participation in another trial with an investigational drug within 3 months prior to administration up to end-of-study examination
  10. Smoker (>10 cigarettes/day or inability to refrain from smoking during the trial)
  11. Alcohol abuse (more than 60 g/day; confirmed by interview)
  12. Drug abuse (confirmed by interview)
  13. Blood donation (more than 100 mL from 3 months prior to screening and any blood donation from screening up to end-of-study examination)
  14. Excessive physical activities (within 7 days prior to the first drug administration up to end-of-study examination)
  15. Any laboratory value outside the reference range that was of clinical relevance
  16. Known hypersensitivity to the investigational drug or its excipients
  17. Subject who was judged ineligible by the investigator or the sub-investigator
  18. History of any familial bleeding disorder
  19. Thrombocytes < 15 x 104 /μL

Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02171000     History of Changes
Other Study ID Numbers: 1160.55
First Posted: June 23, 2014    Key Record Dates
Last Update Posted: June 23, 2014
Last Verified: June 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Dabigatran
Antithrombins
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anticoagulants